Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline
Methodological detailsGRADE approach, linked systematic review and pairwise meta-analysis, international panel including patient partners
- GRADE approach
- Linked systematic review and pairwise meta-analysis
- International panel including patient partners
Recommendations
As issued by the authors
- Weak recommendation in favour
Proactive therapeutic drug monitoring (TDM) for intravenous infliximab during maintenance treatment
- Weak recommendation against
Proactive TDM for adalimumab and other biologic drugs during maintenance treatment
- Weak recommendation against
Proactive TDM for intravenous infliximab, adalimumab, and other biologic drugs during induction (start) of treatment
Original publication
Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline. BMJ. Published 28 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →